Trial · NCT03223337
Results by group540
Each measurement the trial posted, group by group, in the words and numbers it posted.
41 to 60 of 540
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Part 1: Percentage of AUC (0-infinity) Obtained by Extrapolation (Percentage AUCex) of GSK1278863 and Its Metabolites | Part 1: Moderate Hepatic Impairment Participants | GSK2531401 (M13) | 0.2983 | Standard Deviation 0.27141 | Percentage of AUCex |
| Part 1: Percentage of AUC (0-infinity) Obtained by Extrapolation (Percentage AUCex) of GSK1278863 and Its Metabolites | Part 1: Healthy Participants | GSK2531401 (M13) | 0.2787 | Standard Deviation 0.15617 | Percentage of AUCex |
| Part 2: Percentage AUCex of GSK1278863 and Its Metabolites | Part 2: Mild Hepatic Impairment Participants | GSK1278863 | 0.1148 | Standard Deviation 0.26035 | Percentage of AUCex |
| Part 2: Percentage AUCex of GSK1278863 and Its Metabolites | Part 2: Healthy Participants | GSK1278863 | 0.0601 | Standard Deviation 0.06032 | Percentage of AUCex |
| Part 2: Percentage AUCex of GSK1278863 and Its Metabolites | Part 2: Mild Hepatic Impairment Participants | GSK2391220 (M2) | 0.2943 | Standard Deviation 0.32698 | Percentage of AUCex |
| Part 2: Percentage AUCex of GSK1278863 and Its Metabolites | Part 2: Healthy Participants | GSK2391220 (M2) | 0.8105 | Standard Deviation 1.60084 | Percentage of AUCex |
| Part 2: Percentage AUCex of GSK1278863 and Its Metabolites | Part 2: Mild Hepatic Impairment Participants | GSK2487818 (M4) | 0.2584 | Standard Deviation 0.30727 | Percentage of AUCex |
| Part 2: Percentage AUCex of GSK1278863 and Its Metabolites | Part 2: Healthy Participants | GSK2487818 (M4) | 0.9054 | Standard Deviation 0.89147 | Percentage of AUCex |
| Part 2: Percentage AUCex of GSK1278863 and Its Metabolites | Part 2: Mild Hepatic Impairment Participants | GSK2506102 (M5) | 0.5138 | Standard Deviation 0.22859 | Percentage of AUCex |
| Part 2: Percentage AUCex of GSK1278863 and Its Metabolites | Part 2: Healthy Participants | GSK2506102 (M5) | 1.5924 | Standard Deviation 1.69300 | Percentage of AUCex |
| Part 2: Percentage AUCex of GSK1278863 and Its Metabolites | Part 2: Mild Hepatic Impairment Participants | GSK2506104 (M3) | 0.2565 | Standard Deviation 0.28382 | Percentage of AUCex |
| Part 2: Percentage AUCex of GSK1278863 and Its Metabolites | Part 2: Healthy Participants | GSK2506104 (M3) | 0.6875 | Standard Deviation 1.33005 | Percentage of AUCex |
| Part 2: Percentage AUCex of GSK1278863 and Its Metabolites | Part 2: Mild Hepatic Impairment Participants | GSK2531398 (M6) | 0.2915 | Standard Deviation 0.25350 | Percentage of AUCex |
| Part 2: Percentage AUCex of GSK1278863 and Its Metabolites | Part 2: Healthy Participants | GSK2531398 (M6) | 0.9412 | Standard Deviation 0.94415 | Percentage of AUCex |
| Part 2: Percentage AUCex of GSK1278863 and Its Metabolites | Part 2: Mild Hepatic Impairment Participants | GSK2531401 (M13) | 0.2327 | Standard Deviation 0.23338 | Percentage of AUCex |
| Part 2: Percentage AUCex of GSK1278863 and Its Metabolites | Part 2: Healthy Participants | GSK2531401 (M13) | 0.5256 | Standard Deviation 0.46352 | Percentage of AUCex |
| Part 1: Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration (AUC [0-t]) of GSK1278863 and Its Metabolites | Part 1: Moderate Hepatic Impairment Participants | GSK1278863 | 296.1035 | Geometric Coefficient of Variation 111.2 | Hour*nanogram per milliliter |
| Part 1: Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration (AUC [0-t]) of GSK1278863 and Its Metabolites | Part 1: Healthy Participants | GSK1278863 | 148.2504 | Geometric Coefficient of Variation 31.8 | Hour*nanogram per milliliter |
| Part 1: Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration (AUC [0-t]) of GSK1278863 and Its Metabolites | Part 1: Moderate Hepatic Impairment Participants | GSK2391220 (M2) | 77.4861 | Geometric Coefficient of Variation 57.0 | Hour*nanogram per milliliter |
| Part 1: Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration (AUC [0-t]) of GSK1278863 and Its Metabolites | Part 1: Healthy Participants | GSK2391220 (M2) | 46.9368 | Geometric Coefficient of Variation 31.0 | Hour*nanogram per milliliter |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03223337/results?page=3